Keyvelop

Keyvelop is an early-stage biotechnology company focused on developing next-generation oral therapeutics for metabolic diseases, including obesity and type 2 diabetes. The company utilizes a proprietary drug delivery and formulation platform designed to improve the bioavailability and efficacy of molecules that are traditionally difficult to deliver orally. By focusing on G protein-coupled receptors (GPCRs) and other validated metabolic targets, Keyvelop aims to provide patient-friendly alternatives to injectable therapies. The company is currently advancing its lead programs through pre-clinical development to establish proof-of-concept for its oral delivery technology.